COMMUNIQUÉ DE PRESSE publié le 29/01/2024 à 11:02, il y a 9 mois 23 jours Original-Research: Avemio AG (von GBC AG): Kaufen Avemio AG veröffentlicht vorläufige Zahlen für das abgelaufene Geschäftsjahr 2023 und bestätigt das Kauf-Rating trotz Umsatz- und Ergebnisrückgang. Neue Prognose und Kursziel von 32,00 EUR für 2024. Solide Kapitalausstattung und M&A-Wachstum geplant Avemio AG Geschäftsjahr 2023 Kauf-Rating Prognose Reduziert M&A-Wachstum
COMMUNIQUÉ DE PRESSE publié le 29/01/2024 à 11:01, il y a 9 mois 23 jours Original-Research: Avemio AG (von GBC AG): BUY Avemio AG's sales and earnings for 2023 fell short of expectations, leading to reduced forecasts and a target price adjustment to 32.00 EUR. Despite challenges, the company maintains a solid capital base and plans for M&A growth Earnings Forecast Avemio AG GBC AG Sales Decline Target Price Adjustment
COMMUNIQUÉ DE PRESSE publié le 24/01/2024 à 11:36, il y a 9 mois 28 jours Original-Research: Avemio AG (von Montega AG): Kaufen Avemio AG überraschend mit Prognoseanpassung und geplanten IT- und Softwarebereichen. Montega AG stuft Empfehlung auf 'Kaufen' mit neuem Kursziel von 27,00 Euro hoch Montega AG Avemio AG Kaufempfehlung Prognoseanpassung IT-Bereiche
COMMUNIQUÉ DE PRESSE publié le 24/01/2024 à 11:21, il y a 9 mois 28 jours Original-Research: Avemio AG (von Montega AG): Kaufen (zuvor: Halten) Montega AG stuft Avemio AG hoch - Umsatzprognose und Kursziel gesenkt, dennoch Kaufempfehlung. Abweichungen im Umsatz und EBITDA, insbesondere in BPM Broadcast & Professional Media GmbH und VDH Video Data Handels GmbH Montega AG Avemio AG Kaufempfehlung Aktienanalyse Umsatzprognose
COMMUNIQUÉ DE PRESSE publié le 22/01/2024 à 13:55, il y a 9 mois 30 jours Avemio AG remains on course for growth after forecast adjustment for 2023 – market weakness opens up attractive opportunities for M&A activities Avemio AG, a leading system supplier for hardware and software in the field of broadcast as well as professional media, has adjusted its forecast for the 2023 financial year due to market weakness but remains on course for growth with attractive opportunities for M&A activities. The company aims to strengthen profitability and accelerate the realization of already planned synergies from the acquisitions made. Despite challenging market conditions, the Executive Board believes that Avemio AG is in a stable market position to benefit from the growth potential and the usual catch-up effects of the trading business. The forecast adjustment reflects the company's adaptation to the current market environment. Avemio AG's CEO, Ralf P. Pfeffer, highlights the company's ambitions and experience in the European market environment and emphasizes the opportunities presented by the current market weakness. For further details, the webcast presentation tomorrow will provide insights into the company's current development and strategies for the future. Profitability Avemio AG Forecast Adjustment M&A Activities Market Weakness
COMMUNIQUÉ DE PRESSE publié le 22/01/2024 à 13:40, il y a 9 mois 30 jours EQS-Adhoc: Avemio AG: Forecast adjustment for 2023 financial year Avemio AG has announced a forecast adjustment for the 2023 financial year due to an unexpectedly weak final quarter in the trading business. The company plans to accelerate the realization of planned synergies from acquisitions and the integration of existing subsidiaries to strengthen profitability in the changed market environment. The Executive Board now expects a lower revenue and EBITDA for the year based on preliminary figures for the fourth quarter. Despite the challenging market conditions, Avemio AG believes it is in a stable market position to benefit from the growth potential and high-margin digitization business in conjunction with the recovery of the economy. Profitability 2023 Financial Year Avemio AG Forecast Adjustment Trading Business
COMMUNIQUÉ DE PRESSE publié le 29/08/2023 à 12:45, il y a 1 année 2 mois Avemio AG appoints Steffen Schenk as COO
COMMUNIQUÉ DE PRESSE publié le 17/08/2023 à 10:06, il y a 1 année 3 mois Original-Research: Avemio AG (von GBC AG): Kaufen
COMMUNIQUÉ DE PRESSE publié le 16/08/2023 à 14:01, il y a 1 année 3 mois Original-Research: Avemio AG (von Montega AG): Halten
COMMUNIQUÉ DE PRESSE publié le 30/03/2023 à 14:52, il y a 1 année 7 mois EQS-Adhoc: Avemio AG: Increase in Shareholding
Publié le 21/11/2024 à 06:58, il y a 7 heures 17 minutes Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 7 heures 17 minutes Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 7 heures 17 minutes Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 18 heures 8 minutes Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 18 heures 55 minutes Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Publié le 21/11/2024 à 14:00, il y a 15 minutes Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Publié le 21/11/2024 à 14:00, il y a 15 minutes Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Publié le 21/11/2024 à 14:00, il y a 15 minutes Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Publié le 21/11/2024 à 13:30, il y a 45 minutes AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Publié le 21/11/2024 à 13:41, il y a 34 minutes Original-Research: Pentixapharm Holding AG (von BankM AG): Kaufen
Publié le 21/11/2024 à 12:35, il y a 1 heure 40 minutes audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Publié le 21/11/2024 à 12:15, il y a 2 heures Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven